The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through

Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' narrative. UnitedHealth Group is charging patients a markup for key life-saving drugs that could easily exceed their cost by a factor of ten or more,

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the controversial drug middlemen as the agency’s first report released last summer — but relies on more data.

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal Trade Commission (FTC) uncovered in its second interim staff report rele | The FTC released its second interim staff report Tuesday during Chair Lina Khan's final open commission meeting,

FTC said the "Big 3 PBMs" — CVS’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx — imposed markups of hundreds to thousands of percent on critical drugs, including those ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.